Inactive Instrument

News Ceapro Inc. Other OTC

Stocks

CRPOF

CA1499071076

Biotechnology & Medical Research

All News

24-06-03	Aeterna and Ceapro Brief: Cos Complete Merger Transaction; New Name Expected to be Announced in Coming Weeks and Details of AGM Expected to be Announced Shortly	MT
24-06-03	Aeterna Zentaris and Ceapro Complete Merger Transaction	GL
24-06-03	Canadian Investment Regulatory Organization Trading Halt - CZO	AQ
24-06-02	Aeterna Zentaris Inc. completed the acquisition of Ceapro Inc. in a merger of equals transaction.	CI
24-05-29	Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update	AQ
24-05-29	Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-05-29	Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update	GL
24-04-29	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-29	Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	AQ
24-04-29	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-29	Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	GL
24-03-28	Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	MT
24-03-28	Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris	GL
24-03-12	Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	GL
24-02-26	Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	AQ
24-02-26	Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company	GL
24-02-23	Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	GL
24-02-15	Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris	GL
23-12-14	Canadian Investment Regulatory Organization Trade Resumption - CZO	AQ
23-12-14	Canadian Investment Regulatory Organization Trading Halt - CZO	AQ
23-12-13	Aeterna Zentaris Inc. entered into a definitive agreement to acquire Ceapro Inc. for CAD 21.3 million in a merger of equals transaction.	CI
23-12-13	Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides	MT
23-12-13	Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation	CI
23-12-13	Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	GL
23-12-13	Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	AQ